In the high-stakes world of neuro-oncology, few diagnoses carry the clinical weight and emotional gravity of recurrent glioblastoma (GBM). As one of the most aggressive and lethal forms of brain cancer, GBM is characterized by rapid cellular proliferation and an almost inevitable tendency to recur after initial treatment. However, a recent milestone in the first-in-human REGAIN study has provided a glimmer of hope, as Alpha Tau Medical reports a 100% overall response rate in its early-stage clinical trial of Alpha Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT).
The results, which have sent ripples of excitement through the oncology community, suggest that this novel, minimally invasive technology may offer a paradigm shift in how we approach non-resectable brain tumors.
The Core Innovation: What is Alpha DaRT?
Developed initially by researchers at Tel Aviv University and refined by Alpha Tau Medical—a company founded in 2016—Alpha DaRT represents a departure from conventional external-beam radiotherapy. Standard radiation therapy often struggles to balance the destruction of malignant cells with the preservation of surrounding, highly sensitive healthy brain tissue.
Alpha DaRT, by contrast, utilizes intratumoral delivery. By deploying radioactive sources directly into the tumor, the therapy releases alpha-particle emitters that travel only a few micrometers, effectively "painting" the tumor with high-energy radiation from within. This allows for the destruction of solid tumor cells while sparing the adjacent healthy architecture, a critical factor in maintaining neurological function in patients whose tumors are located in delicate, eloquent regions of the brain.
Chronology of the REGAIN Study (NCT06910306)
The journey of the REGAIN study has been marked by rapid clinical translation and careful, methodical execution.
- September 2024: Alpha Tau Medical reaches a significant regulatory milestone when the US Food and Drug Administration (FDA) approves an Investigational Device Exemption (IDE) to evaluate Alpha DaRT in immunocompromised patients with recurrent cutaneous squamous cell carcinoma (cSCC), establishing a foundation of trust with federal regulators.
- May 2026: The company announces the successful treatment of the first three patients in the brain tumor cohort of the REGAIN study. These early procedures established the feasibility of the delivery method.
- November 11, 2026: The data cutoff for the current interim analysis. By this date, eight patients had been treated at the Ohio State University Comprehensive Cancer Center – James. All procedures were performed successfully using burr-hole access and real-time neuronavigation, bypassing the need for invasive open craniotomies.
- Present: The study continues to enroll patients toward a target of 20, with the clinical team monitoring the progress of the initial cohort as they reach long-term follow-up intervals.
Supporting Data: An Unprecedented Response
The data emerging from the first eight patients is, by all traditional metrics, extraordinary. Among the six evaluable participants, the study reported a 100% overall response rate (ORR).
Key Performance Metrics:
- Complete Response (CR): Five of the six evaluable patients achieved a complete response, meaning no evidence of the tumor remained visible on follow-up imaging.
- Partial Response (PR): One patient achieved a 58% reduction in tumor volume.
- Survival: As of the November 11 reporting, all eight treated patients remain alive. With a median follow-up of 6.9 months, the median overall survival (OS) has not yet been reached, a notable feat for a cohort of recurrent GBM patients whose prognosis is typically measured in weeks or a few months.
- Safety Profile: Perhaps the most vital aspect of the study is its safety record. Investigators recorded no unanticipated serious adverse events (AEs) or permanent, procedure-related neurological deficits. While four patients exhibited signs of asymptomatic or suspected radiation necrosis—a known phenomenon where tissue dies due to the effects of radiation—this is often viewed as a trade-off for effective tumor eradication in such a lethal environment.
Clinical Methodology: Precision Engineering in the Brain
The surgical approach used at the Ohio State University Comprehensive Cancer Center – James has been a cornerstone of the study’s success. Rather than performing a traditional craniotomy—which involves removing a large section of the skull and carries significant risks of infection, prolonged recovery, and neurological impact—clinicians utilized a minimally invasive approach.
Using burr-hole access (small, precise holes drilled into the skull) combined with real-time neuronavigation, the team was able to place the Alpha DaRT sources with surgical precision. This methodology allows for the delivery of high-dose radiation directly to the heart of the tumor while the patient remains under anesthesia, significantly reducing the physical burden of the intervention.
Official Responses and Strategic Vision
The leadership at Alpha Tau Medical is optimistic, viewing these results not just as a successful trial, but as the potential foundation for a new standard of care in neuro-oncology.

Uzi Sofer, CEO of Alpha Tau Medical, expressed his sentiments during the latest investor briefing: "In May, we shared the first three patients treated with Alpha DaRT in the brain. Six months later, we see how truly transformational Alpha DaRT could be for recurrent GBM. Eight patients have been treated, every procedure has gone as planned, and every one of those patients is alive."
Sofer noted that the clinical reality has surpassed the company’s internal projections. "The trial thus far has exceeded our wildest expectations, particularly in such a difficult cancer. GBM is one of the most devastating diagnoses in oncology, and recurrence is virtually inevitable. We look forward to following these patients’ progress as their scans mature, and to continuing enrollment toward 20 patients, which we believe, based on initial discussions, may support market submission requirements for Alpha DaRT in patients with this disease."
Implications for the Future of Oncology
The implications of these interim results are far-reaching, both for the medical community and for patients facing terminal brain cancer diagnoses.
1. A New Pathway for Non-Resectable Tumors
The primary challenge in GBM is that tumors often grow in areas where surgical removal is impossible due to the risk of damaging essential brain functions. Alpha DaRT’s ability to "treat" rather than "cut" provides a pathway for patients who were previously deemed to have no surgical options.
2. Regulatory Acceleration
By reaching a 100% response rate in the initial cohort, Alpha Tau Medical is in a strong position to engage in expedited discussions with the FDA. If the final data from the 20-patient study mirrors these initial results, Alpha DaRT could qualify for accelerated approval pathways, potentially bringing the therapy to the broader market years sooner than traditional devices.
3. Broadening the Scope of Alpha-Emitter Technology
While this study focuses on GBM, the underlying technology has applications across various solid tumors. With ongoing studies in cutaneous squamous cell carcinoma, Alpha Tau is building a robust portfolio of evidence that suggests alpha-emitters could become a staple of local tumor control across oncology.
4. Improving Quality of Life
The shift from open craniotomy to minimally invasive burr-hole procedures is more than a technical preference; it is a quality-of-life imperative. Patients with recurrent GBM are often frail; minimizing the surgical trauma allows them to maintain their neurological status and return to their daily lives much faster than those undergoing traditional open-brain surgery.
Conclusion: Cautionary Optimism
While the results from the REGAIN study are undoubtedly impressive, the medical community remains cautiously optimistic. Glioblastoma is a notoriously heterogeneous disease, and "suspected necrosis" in two patients requires careful longitudinal monitoring to ensure that the positive clinical signs are indeed due to tumor regression rather than transient inflammatory responses.
However, the fact that all eight patients remain alive and that the procedure has been proven both safe and feasible at the clinical level marks a significant step forward. As the study continues to enroll toward its 20-patient goal, the oncology world will be watching closely. If these results hold, Alpha DaRT could represent the most significant advancement in the management of recurrent glioblastoma in over a decade, offering a lifeline to patients who had previously been told there was nowhere left to turn.
